Advances in Vision Research, Volume IV

Part I Gene therapy for ocular genetic diseases.- Chapter 1 Gene therapy for neovascular age-related macular degeneration.- Chapter 2 Gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR.- Chapter 3 Optogenetic approaches to restore vision.- Chapter 4 Retinal AAV8-RS1 Gene Therapy for X-Linked Retinoschisis.- Chapter 5 Subretinal versus Intravitreal Delivery of AAV8 in Nonhuman Primates.- Chapter 6 Gene therapy for Leber Congenital Amaurosis caused by mutation in RPE65.- Chapter 7 Release of rAAV Vectors from APMA-Functionalized Contact Lenses for Corneal Gene Therapy.- Chapter 8 Gene Therapy to Prevent Retinal Ganglion Cell Loss in Glaucoma and Leber's Hereditary Optic Neuropathy.- Part II Gene editing as therapy for ocular disease.- Chapter 9 Gene Therapy for Glaucoma by Ciliary Body Aquaporin 1 Disruption Using CRISPR-Cas9.- Chapter 10 Somatic Gene Editing of GUCY2D by AAV-CRISPR/Cas9 in Mouse and Macaque.- Chapter 11 In Vivo CRISPR/Cas9-Mediated Genome Editing Mitigates Photoreceptor Degeneration in Mouse Model of X-Linked Retinitis Pigmentosa.- Chapter 12 Gene Expression and Editing in Mammalian Retinal Ganglion Cells.- Chapter 13 AAV-mediated mutation replacement genome editing in photoreceptors restores vision in mice.- Chapter 14 Gene Editing Preserves Visual Functions in a Mouse Model of Retinal Degeneration.- Chapter 15 Genome Editing as Treatment for Autosomal Dominant Retinitis Pigmentosa.- Chapter 16 CRISPR/Cas base editors to target the AMD high-risk variant.- Part III Cell therapy for ocular genetic diseases.- Chapter 17 Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration.- Chapter 18 Transplantation Retinal Sheet Differentiated from Patient iPS Cells with Inherited Retinitis Pigmentosa.- Chapter 19 Clinical study of an ES cell-derived retinal pigment epithelium patch in age-related macular degeneration.- Chapter 20 Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients.- Chapter 21 Preclinical safety studies of human embryonic stem cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration.- Chapter 22 Corneal endothelial cell derivation methods from ES and iPS cells.- Chapter 23 Gene editing approach to restore vision loss in Leber Congenital Amaurosis type 10.- Chapter 24 Inhibition of Optineurin - TANK Binding Kinase 1 interaction to suppress inherited normal tension glaucoma.- Chapter 25 A 3D Printed Self-Sustainable Cell-Encapsulation Drug Delivery Device for Periocular Transplant-Based Treatment of Retinal Degenerative Diseases.- Chapter 26 Complement inhibition as therapy for retinal diseases.- Chapter 27 Neuroprotective Therapy for Retinal Ganglion Cell Degeneration.- Chapter 28 Artificial intelligence in retina.- Chapter 29 Prediction of AI for Treatment Potential for Macular Cone Vision in Leber Congenital Amaurosis.- Chapter 30 Artificial Intelligence for Evaluation of Macular Degeneration and Suspected Glaucoma.- Chapter 31 Artificial Intelligence Classification of Central Visual Field Patterns in Glaucoma.- Chapter 32 Artificial intelligence and deep learning in ophthalmology.

Este título pertence ao(s) assunto(s) indicados(s). Para ver outros títulos clique no assunto desejado.

• Pesquisa médica
• Oftalmologia
• Genética médica

Translational research;Genetic eye diseases;Gene therapy;Gene editing;Tissue replacement;Stem cell;Artificial eye;Artificial intelligence